Myelodysplastic Syndromes Clinical Trials

A listing of 85 Myelodysplastic Syndromes clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Myelodysplastic Syndromes

1 - 12 of 85

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 85 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

NCT02211755

Recruiting

Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and efficacy of the drug combination of bortezomib and clofarabine. Eligibility: - Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy. Design: * Participants will be screened... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

03/21/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas

Learn More ›

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446

Recruiting

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/20/2025

Locations: Innovative Clinical Research Institute Whittier, Lakewood, California +44 locations

Innovative Clinical Research Institute Whittier, Lakewood, California

David Geffen School of Medicine at UCLA, Los Angeles, California

Emad Ibrahim, MD, Inc., Redlands, California

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida

Edward H. Kaplan MD & Associates, Skokie, Illinois

Washington University School of Medicine, Saint Louis, Missouri

Memorial Sloan Kettering Cancer Center, Long Island City, New York

Duke Adult Blood and Marrow Clinic, Durham, North Carolina

Monash Health, Monash Medical Centre, Clayton, Victoria

Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich

Fakultni nemocnice Ostrava, Ostrava, Not set

Hôpital de La Conception, Marseille, Bouches-du-Rhône

CHU Angers, Angers, Maine-et-Loire

CHRU Lille, Lille, Not set

Hôpital Saint Louis, Paris, Not set

Medizinische Hochschule Hannover, Hannover, Niedersachsen

Universitatsklinikum Dusseldorf, Düsseldorf, Nordrhein-Westfalen

Universitatsklinikum Leipzig, Leipzig, Sachsen

University Hospital of Alexandroupolis, Alexandroupolis, Not set

Attikon University General Hospital, Athens, Not set

University General Hospital of Patras, Patras, Not set

Hippokration Hospital, Thessaloniki, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Tel Aviv Sourasky Medical Center PPDS, Tel Aviv, Not set

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia

Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Lombardia

Istituto Clinico Humanitas, Rozzano, Lombardia

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte

Fondazione PTV Policlinico Tor Vergata, Roma, Not set

Kyungpook National University Hospital, Daegu, Not set

Asan Medical Center - PPDS, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

MTZ Clinical Research Powered by PRATIA - PPDS, Warszawa, Mazowieckie

Pratia Onkologia Katowice - PRATIA - PPDS, Katowice, Slaskie

SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Warminsko-mazurskie

C.H. Regional Reina Sofia - PPDS, Cordoba, Not set

Hospital Universitario La Paz - PPDS, Madrid, Not set

Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Not set

Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Not set

Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Not set

Aberdeen Royal Infirmary - PPDS, Aberdeen, Aberdeen City

Western General Hospital Edinburgh - PPDS, Edinburgh, Not set

Kings College Hospital, London, Not set

Churchill Hospital-NHS Oxford, Oxford, Not set

Conditions: Myelodysplastic Syndromes

Learn More ›

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196

Recruiting

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1 (Dose Escalation) will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1 of the study. Phase 1b (Dose Expansion... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/18/2025

Locations: University of California Los Angeles, Los Angeles, California +8 locations

Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia

Learn More ›

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

NCT05434598

Recruiting

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Whole Genome Sequencing, Myelodysplastic Syndromes

Learn More ›

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT03802695

Recruiting

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

03/14/2025

Locations: City of Hope, Duarte, California +7 locations

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia

Learn More ›

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684

Recruiting

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: Community Cancer Institute, Clovis, California +167 locations

Community Cancer Institute, Clovis, California

John Muir Medical Center - Concord Campus, Concord, California

Compassionate Cancer Care Medical Group, Fountain Valley, California

Local Institution - 0095, Fresno, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California

St. Joseph Hospital, Orange, California

Ventura County Hematology Oncology Specialists, Oxnard, California

Local Institution - 0098, Fort Collins, Colorado

Hartford Hospital (HH), Hartford, Connecticut

Yale-New Haven Hospital, New Haven, Connecticut

Halifax Health Medical Center, Daytona Beach, Florida

Local Institution - 0230, Daytona Beach, Florida

Florida Cancer Specialists - South, Fort Myers, Florida

Baptist MD Anderson Cancer Center, Jacksonville, Florida

D&H Cancer Research Center LLC, Margate, Florida

BRCR Global, Plantation, Florida

Florida Cancer Specialists - North, Saint Petersburg, Florida

Advanced Research, Tamarac, Florida

Moffitt Cancer Center, Tampa, Florida

Local Institution - 0240, Honolulu, Hawaii

Northwestern Memorial Hospital, Chicago, Illinois

Orchard Healthcare Research Inc., Skokie, Illinois

Northwest Cancer Centers, P.C., Dyer, Indiana

Local Institution - 0232, Pikeville, Kentucky

Our Lady of the Lake RMC, Baton Rouge, Louisiana

Pontchartrain Cancer Center, Covington, Louisiana

Local Institution - 0097, New Orleans, Louisiana

American Oncology Partners of Maryland, PA, Bethesda, Maryland

Metro-Minnesota Community Clinical Oncology, Saint Louis Park, Minnesota

Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Tennessee Medical Center, Knoxville, Tennessee

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 0236, Richmond, Virginia

Blue Ridge Cancer Care, Roanoke, Virginia

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Local Institution - 0213, Seattle, Washington

Centro Mdico "Barrio Parque", Buenos Aires, Not set

Hospital Británico de Buenos Aires, Buenos Aires, Not set

Local Institution - 0009, Ciudad Autónoma de Buenos Aires, Not set

Blacktown Hospital, Blacktown, New South Wales

Royal Prince Alfred Hospital, Camperdown, New South Wales

Coffs Harbour Health Campus, Coffs Harbour, New South Wales

Pindara Private Hospital, Gold Coast, Queensland

Monash Health, Clayton, Victoria

Austin Health, Heidelberg, Victoria

Hospital Universitario Walter Cantidio, Fortaleza, Ceará

Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul

HEMORIO, Rio de Janeiro, Not set

Hospital das Clinicas FMUSP, São Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta

St. Paul's Hospital, Vancouver, British Columbia

Victoria Hospital & Children's Hospital - London Health Sciences Centre, London, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

Enroll SpA, Santiago, Región Metropolitana De Santiago

FALP, Santiago, Región Metropolitana De Santiago

Clínica Inmunocel, Santiago, Región Metropolitana De Santiago

Bradfordhill, Santiago, Región Metropolitana De Santiago

Anhui Provincial Hospital, Hefei, Anhui

Peking University People's Hospital, Beijing, Beijing

Beijing Peking Union Medical College Hospital, Beijing, Beijing

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing

Local Institution - 0096, Fuzhou Fujian, Fujian

The First Affiliated hospital of Xiamen University, Xiamen, Fujian

Local Institution - 0031, Guangzhou, Guangdong

The Second Afilliated Hospital of Hebei Medical University, Shijiazhuang, Hebei

The First Hospital of Harbin, Harbin, Heilongjiang

People's Hospital of Henan Province, Zhengzhou, Henan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Xiangya Hospital Central South University, Changsha, Hunan

Jiangsu Province Hospital, Nanjing, Jiangsu

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

The First Hospital of Jilin University, Changchun, Jilin

The First Hospital of China Medical University, Shenyang, Liaoning

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Shanghai Sixth People's Hospital, Shanghai, Shanghai

Shaanxi provincial people's hospital, Xi'an, Shanxi

West China Hospital of Sichuan University, Cheng Du, Sichuan

Institute of hematology&blood disease hospital, Tianjin, Tianjin

The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang

Hospital Pablo Tobon Uribe, Medellin, Antioquia

Sociedad De Oncologia Y Hematologia Del Cesar, Valledupar, Cesar

Local Institution - 0267, Piedecuesta, Santander

Oncomédica S.A.S, Montería, Not set

Fakultní nemocnice Brno Bohunice, Brno, Brno-město

Fakultni nemocnice Ostrava, Ostrava, Moravskoslezský Kraj

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Centre Hospitalier Universitaire de Nice - Hôpital l'Archet, Nice, Alpes-Maritimes

CHU Bordeaux Haut-Leveque, Pessac, Aquitaine

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau, Tours, Indre-et-Loire

Chu Grenoble Alpes, La Tronche, Isère

Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois, Vandoeuvre lès Nancy, Lorraine

Centre Hospitalier Universitaire d'Angers, Angers, Maine-et-Loire

Gustave Roussy, Villejuif, Val-de-Marne

Hôpital Saint-Louis, Paris, Not set

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Not set

Onkologie Erding, Erding, Bayern

Local Institution - 0250, Kempten, Bayern

Gemeinschaftspraxis für Hämatologie und Onkologie Münster, Münster, Nordrhein-Westfalen

InVO Institut für Versorgungsforschung in der Onkologie, Koblenz, Rheinland-Pfalz

Universitätsklinikum Leipzig, Leipzig, Sachsen

Universitätsklinikum Jena, Jena, Thüringen

Praxis fur Hamatologie und Onkologie, Berlin, Not set

Local Institution - 0028, Berlin, Not set

Universitaetsklinikum Duesseldorf, Düsseldorf, Not set

Local Institution - 0255, Lübeck, Not set

Kliniken Ostalb, Stauferklinikum, Mutlangen, Not set

Gemeinschaftspraxis Dr. med. Björn Schöttker & Dominik Pretscher, Würzburg, Not set

Local Institution - 0242, Patras, Achaḯa

University Hospital of Patras, Patras, Achaḯa

General Hospital of Athens "G. Gennimatas", Athens, Attikí

Local Institution - 0245, Athens, Attikí

Attikon General University Hospital, Chaidari, Attikí

University Hospital of Alexandroupolis, Alexandroupolis, Not set

Local Institution - 0034, Hksar, Not set

Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet, Eger, Heves

Szabolcs Szatmár Bereg Vármegyei Oktatókórház, Nyiregyhaza, Szabolcs-Szatmár-Bereg

Semmelweis Egyetem, Budapest, Not set

All India Institute of Medical Sciences, New Delhi, Delhi

Local Institution - 0235, New Delhi, Delhi

Hemato Oncology Clinic, Ahmedabad, Gujarat

Local Institution - 0273, Ahmedabad, Gujarat

Local Institution - 0177, Bengaluru, Karnataka

Institute of Medical Sciences and Sum Hospital, Bhubaneswar, Odisha

Local Institution - 0185, Hyderabad, Not set

Local Institution - 0186, New Delhi, Not set

Fondazione Policlinico Tor Vergata, Rome, Lazio

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia

ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano

Humanitas, Rozzano, Milano

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte

Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

Grande Ospedale Metropolitano - Presidio Morelli, Reggio Calabria, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Roma, Not set

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma, Verona, Not set

Local Institution - 0123, Kitakyushu-shi, Fukuoka

Local Institution - 0117, Sapporo, Hokkaido

Local Institution - 0126, Amagasaki, Hyogo

Local Institution - 0120, Sagamihara, Kanagawa

Local Institution - 0118, Sendai-shi, Miyagi

Local Institution - 0125, Osaka-sayama, Osaka

Local Institution - 0121, Shimotsuga, Tochigi

Local Institution - 0124, Nagasaki, Not set

Local Institution - 0122, Osaka, Not set

Local Institution - 0119, Tokyo, Not set

Hematológica Alta Especialidad SC, consultorio 830, Huixquilucan, Not set

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Not set

Local Institution - 0156, Oaxaca, Not set

Unidad Médica Onco-hematológica, Puebla, Not set

Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu, Wałbrzych, Dolnośląskie

Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Pratia Onkologia Katowice, Katowice, Not set

MTZ Clinical Research powered by Pratia, Warsaw, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Local Institution - 0237, San Juan, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Catalunya [Cataluña]

Hospital Clinico de Valencia, Valencia, Valenciana, Comunitat

Hospital Universitario Virgen Nieves, Granada, Not set

Hospital La Princesa, Madrid, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Conditions: Myelodysplastic Syndromes

Learn More ›

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT03579875

Recruiting

This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

Gender:

ALL

Ages:

65 years and below

Trial Updated:

03/11/2025

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita

Learn More ›

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

NCT06146257

Recruiting

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximatel... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/10/2025

Locations: City of Hope Medical Center, Duarte, California +7 locations

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes

Learn More ›

The Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia (RENEW)

NCT06499285

Recruiting

This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. Approximately 255 participants will be enrolled, randomized 2:1 to re... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/05/2025

Locations: Study Site 1100, Canton, Ohio +1 locations

Conditions: Myelodysplastic Syndromes

Learn More ›

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

NCT05350748

Recruiting

Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease. Eligibility: People with suspected or confirmed MDS or MDS/MPN. Healthy do... Read More

Gender:

ALL

Ages:

Between 1 day and 120 years

Trial Updated:

03/05/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Myelodysplastic Syndromes

Learn More ›

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NCT03810196

Recruiting

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.

Gender:

ALL

Ages:

25 years and below

Trial Updated:

03/03/2025

Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia

Learn More ›

Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122

Recruiting

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer

Learn More ›

1 - 12 of 85